INFLUENCE OF THE ROUTE AND PHARMACEUTICAL PREPARATION IN INTRA-PATIENT VARIABILITY OF TACROLIMUS SERUM LEVELS IN THE LIVER TRANSPLANT PATIENT
4CPS-150
EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN DIFFERENT PERIODS AFTER LIVER TRANSPLANT
4CPS-149
EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN THE DIFFERENT PERIODS OF THE KIDNEY POST-TRANSPLANT
4CPS-148
ANALYSIS OF INTRA-PATIENT VARIABILITY OF PLASMATIC LEVELS OF TACROLIMUS IN EARLY MAINTENANCE OF RENAL POST-TRANSPLANT
4CPS-147
CLINICAL EXPERIENCE OF OPTIMISING CO-ADMINISTRATION THERAPY OF LOW-DOSE ALLOPURINOL WITH LOW-DOSE THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS ATTENDING A VIRTUAL PHARMACIST CLINIC
4CPS-146
SUBLINGUAL AND ENTERIC TACROLIMUS WHOLE BLOOD LEVELS IN AN INTENSIVE CARE UNIT
4CPS-145
PHARMACOGENETICS AS A TOOL IN DOSE ADJUSTMENT OF IMMUNOSUPPRESSIVE DRUGS: A CASE REPORT
4CPS-144
ESTABLISHMENT OF A PHARMACEUTICAL STANDARDISED INTERVIEW CONCERNING BIOSIMILARS OF INFLIXIMAB IN THE DAYCARE CLINIC OF A GASTROENTEROLOGY DEPARTMENT FOR PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE
4CPS-143
EVALUATION OF KNOWLEDGE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY THE REFERENCE PRODUCT CONCERNING BIOSIMILARS: ROLE OF CLINICAL PHARMACISTS
4CPS-142
ADJUVANT CHEMOTHERAPY AND RELAPSE-ASSOCIATED PROGNOSTIC FACTORS IN OPERABLE BREAST CANCER
4CPS-141
ECONOMIC IMPACT OVER THE PAST 4 YEARS ASSOCIATED WITH BIOLOGICAL THERAPY OPTIMISATION IN RHEUMATIC DISEASES PATIENTS
4CPS-140
HOW PHARMACISTS CAN IMPROVE PATIENTS' CARE MANAGEMENT IN SUBCUTANEOUS ANTIPSORIATIC BIOLOGIC THERAPY
4CPS-139
THE PIRAMID STUDY: PATIENTS TREATED BY MYELOMA ORAL MEDICATION HAVE A BAD COMPLIANCE
4CPS-138
BIOSIMILARS' UTILISATION UNDER HOSPITAL PHARMACY MANAGEMENT POLICY
4CPS-137
NATALIZUMAB: A REVIEW OF ITS USE IN THE MANAGEMENT OF MULTIPLE SCLEROSIS, EXPERIENCE IN A UNIVERSITY HOSPITAL
